GlaxoSmithKline (Spain)-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2009

  1. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET

    NeuroImage, Vol. 46, Núm. 2, pp. 447-458

2006

  1. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1 - Pseudoequilibrium interval and quantification methods

    Journal of Nuclear Medicine, Vol. 47, Núm. 6, pp. 919-928

  2. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 2 - Ketanserin displacement

    Journal of Nuclear Medicine, Vol. 47, Núm. 6, pp. 929-937

2005

  1. SPECT of serotonin transporters using123I-ADAM: Optimal imaging time after bolus injection and long-term test-retest in healthy volunteers

    Journal of Nuclear Medicine, Vol. 46, Núm. 8, pp. 1301-1309